Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5733884 | PMC |
| http://dx.doi.org/10.1016/j.ekir.2017.07.006 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Safety and Efficacy of Deutetrabenazine at High versus Lower Daily Dosages in the ARC-HD Study to Treat Chorea in Huntington Disease.
CNS Drugs
February 2025
Innovative Medicines and Global Clinical Development, Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA, USA.
Background: Huntington disease (HD) is a progressive neurodegenerative disease that causes psychiatric and neurological symptoms, including involuntary and irregular muscle movements (chorea). Chorea can disrupt activities of daily living, pose safety issues, and may lead to social withdrawal. The vesicular monoamine transporter 2 inhibitors tetrabenazine, deutetrabenazine, and valbenazine are approved treatments that can reduce chorea.
View Article and Find Full Text PDFAims: Empagliflozin confers cardioprotective benefits among patients with heart failure, across the range of ejection fraction (EF), regardless of type 2 diabetes status. The long-term cost-effectiveness of empagliflozin for the treatment of heart failure (HF) in the Philippines remains unclear. This study aims to determine the economic benefit of adding empagliflozin to the standard of care (SoC) vs the SoC alone for HF in the Philippines.
View Article and Find Full Text PDFEffects of Retinol, Natural Pea Peptide and Antioxidant Blend in a Topical Formulation: In Vitro and Clinical Evidence.
Dermatol Ther (Heidelb)
December 2024
Department of Cell Biology and Physiology, The Neuroscience Center, College of Life Sciences, Brigham Young University, Provo, UT, 84602, USA.
Introduction: Retinol has a long history of treating skin conditions, including photoaging. However, skin irritation with repeated use of retinol is well documented. The present study assessed the effectiveness of a novel topical formulation, referred to as retinol topical formulation (RTF), to improve the quality of skin health.
View Article and Find Full Text PDFThe Long-Term Cost-Effectiveness of Tirzepatide 5 mg versus Dulaglutide 0.75 mg for the Treatment of People with Type 2 Diabetes in Japan.
Diabetes Ther
December 2024
Toranomon Hospital, 2-2-2, Toranomon, Minato-ku, Tokyo, 105-8470, Japan.
Introduction: This analysis aimed to evaluate the long-term cost-effectiveness of tirzepatide 5 mg versus dulaglutide 0.75 mg (both administered once weekly) in people not achieving glycemic control on metformin, based on the results of the head-to-head SURPASS J-mono trial from a Japanese healthcare payer perspective.
Methods: A cost-utility analysis was performed over a 50-year time horizon using an implementation of the UKPDS Outcomes Model 2 developed in Microsoft Excel.
Cost-effectiveness of the adjuvanted RSVPreF3 vaccine among adults aged ≥60 years in the United States.
Hum Vaccin Immunother
December 2024
Vaccines Value Evidence, GSK, Wavre, Belgium.
Article Synopsis
- Respiratory syncytial virus (RSV) commonly causes respiratory illnesses, especially severe in adults over 60 or those with chronic conditions; a study examined the cost-effectiveness of the RSVPreF3 vaccine for this age group in the US.* -
- A multi-cohort Markov model compared outcomes of not vaccinating versus a one-time vaccination, estimating that vaccinating approximately 52.7 million older adults would save nearly 244,424 quality-adjusted life years (QALYs) at a societal cost of about $4.5 billion over five years.* -
- The analysis indicated that the adjuvanted RSVPreF3 vaccine is cost-effective, with an incremental cost-effectiveness ratio (
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!